Heteroaryl substituted  ansa ‐titanocene anti‐cancer drugs derived from fulvenes and titanium dichloride | Zendy

Rehmann FranzJosef K. | Zendy; Cuffe Laurence P. | Zendy; Mendoza Oscar | Zendy; Rai Dilip K. | Zendy; Sweeney Nigel | Zendy; Strohfeldt Katja | Zendy; Gallagher William M. | Zendy; Tacke Matthias | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Premium

Heteroaryl substituted ansa ‐titanocene anti‐cancer drugs derived from fulvenes and titanium dichloride

Author(s) -

Rehmann FranzJosef K.,

Cuffe Laurence P.,

Mendoza Oscar,

Rai Dilip K.,

Sweeney Nigel,

Strohfeldt Katja,

Gallagher William M.,

Tacke Matthias

Publication year - 2005

Publication title -

applied organometallic chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 71

eISSN - 1099-0739

pISSN - 0268-2605

DOI - 10.1002/aoc.864

Subject(s) - cyclopentadienyl complex , chemistry , fulvenes , fulvene , titanium , medicinal chemistry , stereochemistry , organic chemistry , catalysis

Starting from 2‐furylfulvene (1a) , 2‐thiophenylfulvene (1b) , and 1‐methyl‐2‐pyrrolylfulvene (1c), [1,2‐di(cyclopentadienyl)‐1,2‐di‐(2‐furyl)ethanediyl] titanium dichloride (2a) , [1,2‐di(cyclopentadienyl)‐1,2‐di‐(2‐thiophenyl)ethanediyl] titanium dichloride (2b) , and [1,2‐di(cyclopentadienyl)‐1,2‐bis‐(1‐methyl‐2‐pyrrolyl)ethanediyl] titanium dichloride (2c) were synthesized. When titanocenes (2a–c) were tested against pig kidney carcinoma cells (LLC‐PK), inhibitory concentrations (50%) of 4.5 × 10 −4 M , 2.9 × 10 −4 M and 2.0 × 10 −4 M respectively were observed. Copyright © 2005 John Wiley & Sons, Ltd.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research